Á¦29ȸ ¹éÇ÷º´ ¿¬°üÁúȯ ±¹Á¦Çмú´ëȸ (IACRLRD 2019) - 11¿ù 7ÀÏ : 2019-11-07±³À°ÀÏÀÚ : 2019-11-07
±³À°Àå¼Ò : ±×·£µåÇϾæƮȣÅÚ
±³À°ÁÖÁ¦ :
Á¦29ȸ ¹éÇ÷º´ ¿¬°üÁúȯ ±¹Á¦Çмú´ëȸ (IACRLRD 2019) - 11¿ù 7ÀÏ ÁÖÃÖ±â°ü : ´ëÇÑÇ÷¾×ÇÐȸ
´ã´çÀÚ : ¹Ú¿µ¼ö
¿¬¶ôó : 02-566-5353
À̸ÞÀÏ :
secretariat@iacrlrd2019.org ±³À°Á¾·ù : ³»°ú
Âü¼®¿¹»óÀοø : 200¸í
Èñ¸ÁÆòÁ¡ : 6Á¡
Áö¿ª :
¼¿ïƯº°½Ã±³À°½Ã°£ : 8 ½Ã°£ 20ºÐ
¼¼ºÎ¼ö°·á : 50,000¿ø
ºñ°í ÇöÀåµî·Ï 100,000¿ø
±¸ºÐ ¿ùÀÏ °ÀÇ½Ç ½Ã°£ ±³À°Á¦¸ñ °»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ
±³À°½Ã°£ 11-07 ±×·£µåº¼·ë 09:00~09:25 Infectious Origins of Some Leukemias & What To Do Robert Gallo(University of Maryland)
±³À°½Ã°£ 11-07 ±×·£µåº¼·ë 09:25~09:45 A Novel Epigenetic Drug against Adult T-cell Leukemia Toshiki Watanabe(The University of Tokyo)
±³À°½Ã°£ 11-07 ±×·£µåº¼·ë 09:45~10:05 Overview of Virus Associated Hematologic Malignancies Luigi Chieco-Bianchi(University of Padova)
±³À°½Ã°£ 11-07 ±×·£µåº¼·ë 10:05~10:25 Using HTLV-1/BLV Genomics to Understand Adult T-cell Leukemia Anne Van den Broeke(Jules Bordet Institute - ULB)
±³À°½Ã°£ 11-07 ±×·£µåº¼·ë 10:25~10:45 Can We Cure Adult T Cell Leukemia/Lymphoma? Ali Bazarbachi(American University of Beirut-Medical Center)
±³À°½Ã°£ 11-07 ±×·£µåº¼·ë 11:00~11:45 Translating DNA Repair for Targeting Cancers Kyungjae Myung(Institute for Basic Science, Ulsan National Institute of Science and Technology)
±³À°½Ã°£ 11-07 ±×·£µåº¼·ë 11:45~12:05 DNA Methylation and Hydroxymethylation in Hematologic Differentiation and Transformation Myunggon Ko(Ulsan National Institute of Science and Technology)
±³À°½Ã°£ 11-07 ±×·£µåº¼·ë 12:05~12:25 MDS - The Old and New Moshe Mittelman(Tel Aviv Sourasky Medical Center)
±³À°½Ã°£ 11-07 ±×·£µåº¼·ë 12:25~12:45 Overview of MDS Guillermo Garcia-Manero(MD Anderson Cancer Center)
±³À°½Ã°£ 11-07 ±×·£µåº¼·ë 12:45~13:05 Hypomethylation-based Combination Treatments: Where Epigenetics Meets Immunotherapy Michael Lübbert(University of Freiburg Medical Center)
±³À°½Ã°£ 11-07 ±×·£µåº¼·ë 13:15~13:35 Luncheon Symposium 1: BMS Martin Höglund(Uppsala University)
±³À°½Ã°£ 11-07 ±×·£µåº¼·ë 14:05~14:50 Biological Heterogeneity of AML: Implications for Prognosis and Treatment Clara Bloomfield(The Ohio State University)
±³À°½Ã°£ 11-07 ±×·£µåº¼·ë 14:50~15:10 The Rapidly Evolving Landscape in AML Gert Ossenkoppele(Amsterdam University Medical Center, location VUMC)
±³À°½Ã°£ 11-07 ±×·£µåº¼·ë 15:10~15:30 Curative Treatment Options for Older Patients with AML Hervé Dombret(Saint-Louis Institute for Research/ University of Paris)
±³À°½Ã°£ 11-07 ±×·£µåº¼·ë 15:30~15:50 Development of A Novel FLT3 Inhibitor Hitoshi Kiyoi(Nagoya University)
±³À°½Ã°£ 11-07 ±×·£µåº¼·ë 15:50~16:10 Functional Genomic Approaches to Identifying New Therapeutic Strategies for AML Jeffrey Tyner(Oregon Health & Science University)
±³À°½Ã°£ 11-07 ±×·£µåº¼·ë 16:25~17:10 Approaching Survival of the General Population: The Results of CML Study IV in the Global Context Rüdiger Hehlmann(Heidelberg University)
±³À°½Ã°£ 11-07 ±×·£µåº¼·ë 17:10~17:30 Next Generation Sequencing for Chronic Myeloid Leukemia Susan Branford(Centre for Cancer Biology, SA Pathology)
±³À°½Ã°£ 11-07 ±×·£µåº¼·ë 17:30~17:50 New Horizon for CML Therapy: Treatment Discontinuation (TFR) Giuseppe Saglio(University of Turin)
±³À°½Ã°£ 11-07 ±×·£µåº¼·ë 17:50~18:10 French Experience of CML Management Françoise Guilhot(CHU de Poitiers)
±³À°½Ã°£ 11-07 ±×·£µåº¼·ë 18:10~18:30 Role of Allogeneic Stem Cell Transplantation in CML Jane Apperley(Hammersmith Hospital)